Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 40

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 28, 2012; 18(40): 5793-5798
Published online Oct 28, 2012. doi: 10.3748/wjg.v18.i40.5793

Table 1 Baseline characteristics of patients (n = 238)

Continuous variables (mean ± SD)
Age (yr)	29 ± 8.5
Hemoglobin (g/dL)	11.49 ± 2.45
The mean platelet count (10³/mm³)	145.6 ± 14.3
SGPT (IU/L)	134.18 ± 14.3
Hepatitis B DNA level (IU/mL)	155 × 10³± 70.1 × 10³
Categorical variable, frequency (%)
Sex
Male	180 (75.6)
Female	58 (24.4)
Stage of fibrosis
Stage 2	172 (72.3)
Stage 3	44 (18.5)
Stage 4	22 (9.2)
Biochemical response	122 (51.3)
End of treatment	71 (29.8)
Sustained viral response	70 (29.4)

SGPT: Serum glutamic pyruvic transaminase.

Citation: Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol 2012; 18(40): 5793-5798
URL: https://www.wjgnet.com/1007-9327/full/v18/i40/5793.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i40.5793

Samiullah S, Bikharam D, Nasreen. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol 2012; 18(40): 5793-5798 [PMID: 23155322 DOI: 10.3748/wjg.v18.i40.5793]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.